FDA Investigator Daniel R Azar
Daniel R Azar has conducted inspections on 6 sites in 1 countries as of 30 Aug 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
6
Last Inspection Date:
30 Aug 2023
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Daniel R Azar:
Amber G Chung,
Amos C Epps,
Barbara J Holladay,
Barbara Janine Breithaupt,
Brian R Yaun,
Brooke K Higgins,
Byungja E Marciante,
Chaltu Nwakijra,
Charlean R Butler,
Charles M Kerns, BLT DO,
Charles R Bonapace, PhD,
Christian D Lynch (CDL),
Christine M Whitby, CSO,
Christopher R Wells,
Cynthia A Harris, MD, RN,
Cynthia Jim, CSO,
Debra Bower,
Dennis L Doupnik,
Diane T Bargo,
Diane T O'brien,
Douglas A Campbell,
Dr. Mark J Seaton, PhD,
Dr. Zhou Chen (nmi), MD PhD,
Dung N Tran,
Emest F Bizjak,
Erin L Mcfiren,
Esaw,
Gale L Glinecki,
Jacqueline Mdiaz Albertini,
John M Gusto,
Johnson,
Julie D Bringger,
Jyoti B Patel, PhD,
Karen A Spencer,
Kenneth Nieves,
Kurt A Brorson, PhD,
Lakisha M Williams,
LCDR Cornelius Brown, III,
Linda J Eason,
LT Luis O Rodriguez,
LT Melanie M Mayor, USPHS,
Lynette P Salisbury,
Marcus A Ray,
Michael F Skelly, PhD,
Michael L Zimmerman,
Mohamad A Chahine,
Monique Rac Lester,
Nancy L Meade,
Nebil A Oumer,
Norman K Starks,
Normica G Facey,
Olaide Akinmade,
Osama M Hamoud,
Philip J Snoy,
Rachel C Harrington,
Renisha M Shaw,
Richard Heath Coats,
Rina Bhikha,
Robert L Hummel,
Rose Ashley,
Scott T Panagiotis,
Shelby W Brown, Jr,
Stacey A Priest,
Stephanie L Shapley,
Steven P Donald,
Susan M Jackson,
Tamara N Champion,
Tania E Vizcaino,
Thomas J Hudson,
Timothy M Albright,
Toyin B Oladimeji,
Tressa T Lewis,
Walter L Fava,
Wayne L Jefferson,
William A Warnick,
Zhongren Wu
Daniel R Azar's Documents
Publish Date | Document Type | Title |
---|---|---|
February, 2009 | FDA 483 | BioReliance Corporation - Form 483, 2009-02-18 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more